12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Biotica, NeuroVive deal

NeuroVive acquired a portfolio of cyclophilin inhibitors, technology platform assets and related IP from Biotica. NeuroVive said it plans to use the...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >